Press release
Breast Cancer Market Boosting the Growth of Breast Cancer Industry at a CAGR of 9.2% Till 2023 | By Treatment Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy Etc
Worldwide Segmentation & Deep Study on “Breast Cancer Market” Present by MarkerResearchFuture.com and Provide Overview of Key Players and their Strategic Profiling in the Market, Comprehensively Analyzing their Core Competencies, and Drawing a Competitive Landscape for the MarketLeading Players
The global market consist of players such as Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), and Bayer AG (Germany). These are some of the prominent players at the forefront of competition in the global breast cancer market.
Get Premium Free Sample Report at https://www.marketresearchfuture.com/sample_request/1379
Segmentation Analysis:
Global breast cancer market is segmented on the basis of type into invasive ductal carcinoma, invasive lobular carcinoma and other. On the basis of treatment, they are segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy and other. Chemotherapy is further segmented into antimetabolites, anthracyclines, taxanes and alkylating agents. Target therapy is further segmented into tyrosine kinase inhibitors and monoclonal antibodies Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others. On the basis of end users, the market is segmented into hospital pharmacies, private pharmacies and other.
Global Breast Cancer Market: Overview
According to a recent study published by the Market Research Future analysts, the global breast cancer market is growing at a moderate growth rate; mainly due to rise in the prevalence rate of the breast cancer. Adoption of unhealthy lifestyle, mutations in genetic profile of the patients and continuous exposure to harmful radiations are also responsible for the increase of the breast cancer cases all across the world. Increasing government support, increased investment in the research and development, and rising awareness about the breast cancer among masses also has contributed to the growth of the market.
On the other hand, there are some obstacles in this market such as high cost of the treatment, expensive drugs, and side effects of the treatment. These all factors have negatively affected the widespread growth of overall breast cancer market.
Competitive Dashboard:
The market for breast cancer is well established market with number of companies operating in this market. There are large number of companies involved in the development of the products including the drugs, molecules.
Breast Cancer Market is becoming huge with increasing demand for the treatment options. Unavailability of absolute treatment has given a wide range of platform for the development of the market. Companies are focusing on the development of new products which will be cost effective and will have minimum side effects. Various companies are involved in the development of specific types of molecules, and novel therapies. These companies have adapted the strategies of the acquisitions, and also launching of the new products in order to strive in this big and competitive market. Moreover, competition amongst new market players is also expected to upsurge growth for breast cancer drugs market over the next few years.
Pfizer is among the world's largest pharmaceutical companies headquartered in US. In March 2017, company has got FDA approval of IBRANCE for the first line HR+, HER2- metastatic breast cancer. It is the only cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor approved by the FDA as a first line therapy. In 2016, Pfizer has acquired Medivation to increase its oncology market.
AstraZeneca is an Anglo–Swedish multinational pharmaceutical company headquarters in UK. In 2017, company has got approval for three new drugs. Lynparza is one of three new drugs which is PARP inhibitors. This drug has shown a most promising results in Phase III clinical trials and may generate $1.2 billion by 2020.
Novartis AG is one of the largest Swiss pharmaceutical company. In 2017, company has got FDA approval for Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer with the combination of any aromatase inhibitor. Company has announced collaboration with IBM Watson Health to explore development of new techniques. In 2016, LEE011 is approved by FDA as first-line treatment for breast cancer.
GlaxoSmithKline is the world sixth largest pharmaceutical company headquartered in UK. Tykerb is the most widely used drug of the company. In 2015, GSK has announced its acquisition on GlycoVaxyn which is a Swiss pharmaceutical company.
Hoffmann-La Roche AG is among the five largest pharmaceutical company in the world headquartered in Switzerland. In 2014, Roche has got an FDA approval of Kadcyla (trastuzumab emtansine) which is the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer.
Browse Complete Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/global-breast-cancer-market-1379
Regional Analysis
Breast cancer is one of the major type of cancer in women all across the world. According to WHO, 200,000 new cases are diagnosed worldwide and the number will increased in the coming future. The Americas dominate the global breast cancer market owing to the presence of huge patient population suffering from breast cancer. Moreover, changing lifestyle, and increasing government support, role of cancer care organisations in increasing awareness about the disease in people has also impacted on the growth of the breast cancer market. Europe accounts for the second largest market for the breast cancer, which is followed by Asia Pacific. Asia Pacific is the fastest growing market owing to the huge population base, increasing prevalence of breast cancer, rapidly developing economies and presence of huge opportunity for the growth of the market. The Middle East & Africa has the least market share due to the presence of the poor economies in Africa region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Breast Cancer Market Boosting the Growth of Breast Cancer Industry at a CAGR of 9.2% Till 2023 | By Treatment Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy Etc here
News-ID: 1811544 • Views: …
More Releases from Market Research Future
9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through …
The 9-decanoic acid methyl ester market is a growing sector driven by the increasing demand for bio-based and sustainable chemical products across various industries. With its unique properties, it finds application in flavors and fragrances, pharmaceuticals, personal care, and as a chemical intermediate. The market is projected to expand significantly in the coming years.
Market Overview and Size
The global 9-decanoic acid methyl ester market was valued at USD 230.0 million in…
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
The washable marker market is a dynamic and growing segment within the broader stationery and art supplies industry. Driven by a blend of consumer demands for safety, convenience, and sustainability, the market is experiencing consistent expansion, particularly within the education and home-use sectors. While faced with some challenges, the industry's future looks promising, propelled by product innovation and evolving consumer trends.
Get Sample @ https://www.marketresearchfuture.com/sample_request/41217
Market Size and Growth
The global washable…
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
The phone car mounts market, a critical sub-segment of the broader automotive accessories industry, is experiencing robust growth driven by a convergence of technological advancements, evolving consumer behavior, and increasingly stringent road safety regulations. As smartphones become indispensable for navigation, communication, and in-car entertainment, the demand for secure and convenient hands-free solutions continues to escalate. The global phone car mounts market was valued at USD 3.93 billion in 2024 and…
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR …
Market Overview:
The Intravenous (IV) Solution Market is estimated to be valued at USD 13.9 billion in 2023 and is projected to reach USD 26.60 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.70% from 2024 to 2031. The market growth is attributed to the rising prevalence of chronic diseases, growing hospitalization rates, and increasing surgical procedures that require IV fluid administration. Intravenous solutions are critical…
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
